BioPharma Dive10d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
The Boston Globe10d
Vertex’s non-opioid pain drug gets some UnitedHealth coverage
Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.
The Business Journals27d
Vertex grew headcount 13% for the second straight year
At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript)
Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...
Yahoo Finance3d
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close. We recently published a list of the 11 Best Pharma Stocks to Buy ...
pharmaphorum1d
FDA fast tracks type 1 diabetes cell therapy from Vertex
VX-880 (formerly known as STx-02) derives from Vertex’ near $1 billion acquisition of Semma in 2019, and has started enrolling patients in a phase 1/2 study in the US. The therapy takes the form ...
ZigWheels12d
Hero Pleasure Plus VX
Hero Pleasure Plus VX is the mid variant in the Pleasure Plus lineup and is priced at Rs. 75,213 (ex-showroom, Delhi). This VX variant comes with an engine putting out and of max power and max ...
Investing19d
Vertex Pharmaceuticals’ SWOT analysis: stock outlook mixed as CF leader faces 2025 hurdles
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $123.2 billion, finds itself at a critical juncture as it navigates ...
MarketWatch13d
CBOE Volatility Index Continuous Contract
2-Year U.S. Treasury Note Continuous Contract $103.395-0.109-0.11% 5-Year U.S. Treasury Note Continuous Contract $107.539-0.281-0.26% 10-Year U.S. Treasury Note Continuous Contract $110.469-0.406 ...
BioSpace27d
AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval
AlgoTx’s mid-stage stumble on Tuesday comes after Vertex earlier this month won the FDA’s approval for Journavx, an inhibitor of the NaV1.8 voltage-gated sodium channel that marks the first new ...